Rapid weight loss with tirzepatide increases the risk of gallstones. Here’s how to prevent this complication. Cholelithiasis (gallstones) is an often overlooked side effect of rapid weight loss, regardless of the method used. With tirzepatide, this risk is amplified by the magnitude and speed of weight loss … Read more
Hypoglycemia with tirzepatide is rare due to its glucose-dependent action. However, certain situations increase the risk. One of the major advantages of tirzepatide compared to older antidiabetic treatments is its low risk of hypoglycemia. This safety is linked to its glucose-dependent mechanism of action. However, certain clinical situations warrant particular vigilance. Why is the risk … Read more
Injection site reactions are common but generally benign. Learn how to prevent and treat them. Approximately 3 to 5% of patients on tirzepatide develop injection site reactions. Although rarely serious, these reactions can be bothersome and concerning. Here is a practical guide to prevent and treat them. Types of reactions … Read more
Thyroid risk with GLP-1 is a regular concern. Here’s what human versus animal data say. The FDA’s black box warning regarding the risk of C-cell thyroid tumors with GLP-1 agonists has generated understandable concern among patients. This warning is based on animal data. What about… Read more
Gastroparesis is a rare but potentially debilitating side effect of GLP-1 agonists. Here’s how to recognize and prevent it. Gastroparesis, defined by an abnormal slowing of gastric emptying without mechanical obstruction, has received considerable media attention with the rise of GLP-1 treatments. Although rare, this complication can be debilitating and … Read more
The risk of pancreatitis with tirzepatide is real but low. Knowing the warning signs is essential for rapid management. Pancreatitis is the most closely monitored potentially serious side effect in patients on GLP-1 agonists. Although the risk is very low (0.1 to 0.2% in clinical trials), acute pancreatitis … Read more
Hair loss with GLP-1 agonists is a concern for patients. Here’s what science really says about this phenomenon. Hair loss (alopecia) is a growing concern among patients on GLP-1 agonists, amplified by testimonials on social media. But what do scientific data really say? Is it a … Read more
Fatigue with Mounjaro affects approximately 10 to 15% of patients. Discover its causes and how to regain your energy during treatment. Fatigue is an often underestimated side effect of tirzepatide. While rarely mentioned as a reason for discontinuation in clinical studies, it significantly impacts the quality of life of about 10 to 15% … Read more
Nausea is the most common side effect with Mounjaro. Here’s a comprehensive guide to understanding, preventing, and effectively treating it. Between 24% and 33% of patients on tirzepatide experience nausea, primarily at the beginning of treatment and during dose escalations. Although generally transient, this nausea can significantly affect quality of life and lead some patients to discontinue treatment. … Read more
The SUMMIT study demonstrates that tirzepatide significantly improves symptoms and prognosis of heart failure in obese patients. Heart failure with preserved ejection fraction (HFpEF) is one of the most frequent and challenging forms of heart failure to treat, particularly affecting obese patients. The SUMMIT study, published in the New England … Read more
The SURMOUNT-Jr study paves the way for the treatment of severe obesity in adolescents with tirzepatide, showing superior results to any existing treatment. Pediatric obesity is a global public health crisis. In France, approximately 18% of children and adolescents are overweight or obese, with major physical and psychological consequences. The SURMOUNT-Jr study, … Read more
Discontinuing tirzepatide leads to weight regain in the majority of patients. Here are the scientific data and strategies to limit this phenomenon. One of the most important questions for patients on Mounjaro is: what happens when treatment is stopped? Data from the SURMOUNT-4 study and observational studies provide … Read more